Steve Bender
Impact in
-
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Oncology top 10%
- Pancreatic and Hepatic Oncology Research
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 3
- Angiogenesis and VEGF in Cancer 2
- Oncology 6
- Cancer Cells and Metastasis 2
- HER2/EGFR in Cancer Research 2
- Cancer Treatment and Pharmacology 1
- Co-authors
- Michele McTigue (2 shared papers)Helen Y. Zou (3 shared papers)Maren L. Grazzini (2 shared papers)David R. Shalinsky (2 shared papers)Brion W. Murray (2 shared papers)Robert S. Kania (2 shared papers)Karin Amundson (2 shared papers)Grant Wickman (2 shared papers)
- Journals
- Cancer Research (4 papers)Clinical Cancer Research (2 papers)Molecular Cancer Therapeutics (1 paper)PLoS ONE (1 paper)Journal of Medicinal Chemistry (1 paper)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Steve Bender
9 papers receiving 636 citations
Steve Bender's Hit Papers
Peers
Comparison fields: 5 of 75
- Cancer Research 148
- Oncology 259
- Pulmonary and Respiratory Medicine 269
- Molecular Biology 399
- Pathology and Forensic Medicine 59
Countries citing papers authored by Steve Bender
This map shows the geographic impact of Steve Bender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Bender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Bender more than expected).
Fields of papers citing papers by Steve Bender
This network shows the impact of papers produced by Steve Bender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Bender. The network helps show where Steve Bender may publish in the future.
Co-authors
The 25 scholars most cited alongside Steve Bender, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 Hit paper breakdown → | 2008 | 515 |
| 2 | 2010 | 58 | |
| 3 | 2013 | 33 | |
| 4 | 2006 | 18 | |
| 5 | 2008 | 8 | |
| 6 | 2014 | 8 | |
| 7 | AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo | 2004 | 7 |
| 8 | Receptor tyrosine kinase cross talk affects tumor cell sensitivity to RTK inhibitors | 2008 | 2 |
| 9 | 2010 | 1 |
About Steve Bender
Steve Bender is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Immunology and Cancer Research, having authored 9 papers that have together received 650 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (3 papers), Cancer Genomics and Diagnostics (2 papers), Angiogenesis and VEGF in Cancer (2 papers), Lung Cancer Treatments and Mutations (2 papers), Toxin Mechanisms and Immunotoxins (2 papers), Cancer Cells and Metastasis (2 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer Treatment and Pharmacology (1 paper). The work is most often cited by research in Cancer Research (148 citations), Oncology (259 citations), Pulmonary and Respiratory Medicine (269 citations), Molecular Biology (399 citations) and Pathology and Forensic Medicine (59 citations). Steve Bender has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Michele McTigue, Helen Y. Zou, Maren L. Grazzini, David R. Shalinsky, Brion W. Murray, Robert S. Kania, Karin Amundson, Grant Wickman, Dana D. Hu‐Lowe and David A. Rewolinski. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, PLoS ONE and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.